In last trading session, Aquestive Therapeutics Inc (NASDAQ:AQST) saw 1.94 million shares changing hands with its beta currently measuring 2.80. Company’s recent per share price level of $3.37 trading at $0.04 or 1.20% at ring of the bell on the day assigns it a market valuation of $306.80M. That closing price of AQST’s stock is at a discount of -84.87% from its 52-week high price of $6.23 and is indicating a premium of 62.91% from its 52-week low price of $1.25. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.5 million shares which gives us an average trading volume of 1.69 million if we extend that period to 3-months.

For Aquestive Therapeutics Inc (AQST), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.12. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.

Aquestive Therapeutics Inc (NASDAQ:AQST) trade information

Upright in the green during last session for gaining 1.20%, in the last five days AQST remained trading in the green while hitting it’s week-highest on Wednesday, 07/24/24 when the stock touched $3.37 price level, adding 1.75% to its value on the day. Aquestive Therapeutics Inc’s shares saw a change of 66.83% in year-to-date performance and have moved 8.71% in past 5-day. Aquestive Therapeutics Inc (NASDAQ:AQST) showed a performance of 38.68% in past 30-days. Number of shares sold short was 7.63 million shares which calculate 4.13 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 9.5 to the stock, which implies a rise of 64.53% to its current value. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 12. It follows that stock’s current price would drop -107.72% in reaching the projected high whereas dropping to the targeted low would mean a loss of -107.72% for stock’s current value.

Aquestive Therapeutics Inc (AQST) estimates and forecasts

Statistics highlight that Aquestive Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 34.80% of value to its shares in past 6 months, showing an annual growth rate of -276.92% while that of industry is 13.30. Apart from that, the company came lowering its revenue forecast for fiscal year 2024.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 46.61% during past 5 years.

AQST Dividends

Aquestive Therapeutics Inc is more likely to be releasing its next quarterly report in August and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Aquestive Therapeutics Inc (NASDAQ:AQST)’s Major holders

Insiders are in possession of 5.03% of company’s total shares while institution are holding 46.59 percent of that, with stock having share float percentage of 49.05%. Investors also watch the number of corporate investors in a company very closely, which is 46.59% institutions for Aquestive Therapeutics Inc that are currently holding shares of the company. BRATTON CAPITAL MANAGEMENT, L.P. is the top institutional holder at AQST for having 9.81 million shares of worth $41.79 million. And as of 2024-03-31, it was holding 16.0164 of the company’s outstanding shares.

The second largest institutional holder is VR ADVISER, LLC, which was holding about 5.56 million shares on 2024-03-31. The number of shares represents firm’s hold over 9.0694 of outstanding shares, having a total worth of $23.67 million.